Panmure Gordon & Co, a leading independent institutional stockbroker and investment bank, is pleased to advise that it has acted as Nominated Adviser and sole broker on the IPO of Horizon Discovery Group plc (HZD.L) raising £68.6m. Horizon Discovery Group plc ("Horizon" or "the Company"), the life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines successfully floated on the London Stock Exchange's AIM market following a successful placing by Panmure Gordon (UK) Limited, raising GBP68.6 million from institutional investors comprising GBP40 million for the Company before expenses and the sale of GBP28.6 million of Sale Shares, at a price of 180p per share.  Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc, commented: "Our listing today and the funds raised will fuel Horizon Discovery's ambition to become the global leader in the provision of Life Science research tools that enable the understanding of the genetic basis of disease and the development of personalised medicines.”